Lineage Cell (LCTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...

2025年2月12日， Lineage Cell（LCTX）披露2笔公司内部人交易情况。董事Culley Brian M于2025年2月11日卖出1.25万股。 【公司资料】 Lineage Cell Therapeutics, Inc.于1990年在加利福尼亚州成立。该公司是一家临床阶段的生物技术公司，开发新型同种异体或“现成的”细胞疗法，以满足未满足的医疗需求。公司项目基于公司专有的基于细胞的 ...

About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

A research team from Osaka University investigates the impact of antioxidant enzymes on specific cell types and their role in ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical ...